6.49 USD
+0.21 (+3.34%)
At close: Feb 6, 2026
6.48 USD
-0.01 (-0.15%)
Pre-Market: 2/9/2026, 4:29:40 AM
Overall RNAC gets a fundamental rating of 3 out of 10. We evaluated RNAC against 523 industry peers in the Biotechnology industry. The financial health of RNAC is average, but there are quite some concerns on its profitability. RNAC is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- RNAC had negative earnings in the past year.
- RNAC had a negative operating cash flow in the past year.
- RNAC had negative earnings in 4 of the past 5 years.
- In the past 5 years RNAC reported 4 times negative operating cash flow.
1.2 Ratios
- The Return On Assets of RNAC (-13.58%) is better than 80.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.58% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-22.83%
ROA(5y)-25.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for RNAC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- RNAC does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for RNAC has been increased compared to 1 year ago.
- The number of shares outstanding for RNAC has been increased compared to 5 years ago.
- RNAC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- Based on the Altman-Z score of -2.80, we must say that RNAC is in the distress zone and has some risk of bankruptcy.
- The Altman-Z score of RNAC (-2.80) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.8 |
ROIC/WACCN/A
WACC12.44%
2.3 Liquidity
- RNAC has a Current Ratio of 10.67. This indicates that RNAC is financially healthy and has no problem in meeting its short term obligations.
- RNAC has a better Current ratio (10.67) than 83.94% of its industry peers.
- A Quick Ratio of 10.67 indicates that RNAC has no problem at all paying its short term obligations.
- With an excellent Quick ratio value of 10.67, RNAC belongs to the best of the industry, outperforming 83.94% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.67 | ||
| Quick Ratio | 10.67 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 83.70% over the past year.
- Looking at the last year, RNAC shows a very negative growth in Revenue. The Revenue has decreased by -95.98% in the last year.
- Measured over the past years, RNAC shows a very strong growth in Revenue. The Revenue has been growing by 42.27% on average per year.
EPS 1Y (TTM)83.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.12%
Revenue 1Y (TTM)-95.98%
Revenue growth 3Y-22.95%
Revenue growth 5Y42.27%
Sales Q2Q%16.8%
3.2 Future
- Based on estimates for the next years, RNAC will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.97% on average per year.
- Based on estimates for the next years, RNAC will show a quite strong growth in Revenue. The Revenue will grow by 17.87% on average per year.
EPS Next Y79.52%
EPS Next 2Y30.6%
EPS Next 3Y18.7%
EPS Next 5Y11.97%
Revenue Next Year-95.06%
Revenue Next 2Y-87.84%
Revenue Next 3Y-73.48%
Revenue Next 5Y17.87%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for RNAC. In the last year negative earnings were reported.
- Also next year RNAC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- RNAC's earnings are expected to grow with 18.70% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.6%
EPS Next 3Y18.7%
5. Dividend
5.1 Amount
- No dividends for RNAC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
6.49
+0.21 (+3.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-05 2026-03-05/amc
Inst Owners24.05%
Inst Owner Change2.36%
Ins Owners39.82%
Ins Owner Change2.43%
Market Cap168.74M
Revenue(TTM)1.93M
Net Income(TTM)-50.61M
Analysts82.67
Price Target36.28 (459.01%)
Short Float %20.39%
Short Ratio11.89
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)50.2%
Min EPS beat(2)-60.11%
Max EPS beat(2)160.52%
EPS beat(4)3
Avg EPS beat(4)33.41%
Min EPS beat(4)-60.11%
Max EPS beat(4)160.52%
EPS beat(8)4
Avg EPS beat(8)-112.56%
EPS beat(12)6
Avg EPS beat(12)-65.9%
EPS beat(16)9
Avg EPS beat(16)-57.78%
Revenue beat(2)1
Avg Revenue beat(2)8.97%
Min Revenue beat(2)-64.04%
Max Revenue beat(2)81.99%
Revenue beat(4)2
Avg Revenue beat(4)6.99%
Min Revenue beat(4)-64.04%
Max Revenue beat(4)81.99%
Revenue beat(8)5
Avg Revenue beat(8)195.9%
Revenue beat(12)6
Avg Revenue beat(12)121.23%
Revenue beat(16)9
Avg Revenue beat(16)114.73%
PT rev (1m)0.81%
PT rev (3m)-2.35%
EPS NQ rev (1m)0%
EPS NQ rev (3m)20.78%
EPS NY rev (1m)0%
EPS NY rev (3m)-16.95%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-76.35%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.41%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 87.57 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.15
EYN/A
EPS(NY)-3.44
Fwd EYN/A
FCF(TTM)-2.65
FCFYN/A
OCF(TTM)-2.43
OCFYN/A
SpS0.07
BVpS-1.38
TBVpS-9.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.58% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-22.83%
ROA(5y)-25.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 199.75% | ||
| Cap/Sales | 294.08% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 10.67 | ||
| Quick Ratio | 10.67 | ||
| Altman-Z | -2.8 |
F-Score2
WACC12.44%
ROIC/WACCN/A
Cap/Depr(3y)302.59%
Cap/Depr(5y)221.09%
Cap/Sales(3y)8.41%
Cap/Sales(5y)6.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.12%
EPS Next Y79.52%
EPS Next 2Y30.6%
EPS Next 3Y18.7%
EPS Next 5Y11.97%
Revenue 1Y (TTM)-95.98%
Revenue growth 3Y-22.95%
Revenue growth 5Y42.27%
Sales Q2Q%16.8%
Revenue Next Year-95.06%
Revenue Next 2Y-87.84%
Revenue Next 3Y-73.48%
Revenue Next 5Y17.87%
EBIT growth 1Y-58.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3Y-65.62%
EBIT Next 5Y-21.06%
FCF growth 1Y-71.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-59.18%
OCF growth 3YN/A
OCF growth 5YN/A
CARTESIAN THERAPEUTICS INC / RNAC FAQ
What is the ChartMill fundamental rating of CARTESIAN THERAPEUTICS INC (RNAC) stock?
ChartMill assigns a fundamental rating of 3 / 10 to RNAC.
Can you provide the valuation status for CARTESIAN THERAPEUTICS INC?
ChartMill assigns a valuation rating of 0 / 10 to CARTESIAN THERAPEUTICS INC (RNAC). This can be considered as Overvalued.
How profitable is CARTESIAN THERAPEUTICS INC (RNAC) stock?
CARTESIAN THERAPEUTICS INC (RNAC) has a profitability rating of 1 / 10.
Can you provide the financial health for RNAC stock?
The financial health rating of CARTESIAN THERAPEUTICS INC (RNAC) is 4 / 10.
Can you provide the expected EPS growth for RNAC stock?
The Earnings per Share (EPS) of CARTESIAN THERAPEUTICS INC (RNAC) is expected to grow by 79.52% in the next year.